Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02731521 · ClinicalTrials.gov registry record
Clinical Development of MR Spectroscopy and Imaging in Brain Cancers
A clinical trial, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 112
- Enrollment target
NCT02731521: Completed study, sponsored by University of Texas Southwestern Medical Center.
NCT02731521 is a clinical trial that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 112 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02731521 has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 112 participants
- Enrollment target
Study Summary
The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in isocitrate dehydrogenase (IDH) mutated gliomas and IDH wild type gliomas.
Primary Outcome
Measuring amount of 2-hydroxygluterate (2HG) biomarker with MRS.
Interventions
- DEVICE 3 Tesla Scanning
- DEVICE 7 Tesla Scanning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2014-01 |
| Est. Completion | 2021-12-31 |
What the finished NCT02731521 record still lists
NCT02731521 is an observational study that tracks outcomes without assigning an intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which 3 Tesla Scanning is the first listed.
NCT02731521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02731521 about?
NCT02731521 is a clinical study titled "Clinical Development of MR Spectroscopy and Imaging in Brain Cancers". The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in isocitrate dehydrogenase (IDH) mutated gliomas and IDH wild type gliomas.
What is the current status of trial NCT02731521?
This trial is currently completed. The enrollment target is 112 participants. The study started on 2014-01. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT02731521?
The interventions under investigation include: 3 Tesla Scanning (DEVICE), 7 Tesla Scanning (DEVICE).
Who is sponsoring clinical trial NCT02731521?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia